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Levothyroxine, a largely prescribed drug with a narrow therapeutic index, is often a lifelong 
treatment. The therapeutic efficacy of thyroxine may be marred by behavioral, pharmacologic 
and pathologic issues acting as interfering factors.  Despite a continuous search for an 
optimal thyroxine treatment, a significant number of patients fail to show a complete 
chemical and/or clinical response to this reference dose of thyroxine. Gastrointestinal 
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malabsorption of oral thyroxine represents an emerging cause of refractory hypothyroidism 
and may be more frequent than previously reputed.  
In this review article we aimed at examining the pharmacologic features of thyroxine 
preparations and their linkage with the intestinal absorption of the hormone. We have stressed 
the major biochemical and pharmacologic characteristics of thyroxine and its interaction with 
the putative transporter at the intestinal level. We have examined the interfering role of 
nutrients, foods, and drugs on thyroxine absorption at gastric and intestinal level. The impact 
of gastrointestinal disorders on thyroxine treatment efficacy has been also analyzed, in 
keeping with the site of action and the interfering mechanisms. Based on the evidence 
obtained from the literature, we also propose a schematic diagnostic workup for the most 
frequent and, often hidden, gastrointestinal diseases impairing thyroxine absorption. 
ESSENTIAL POINTS 
• Gastrointestinal malabsorption of thyroxine may account for a significant fraction of refractory 
hypothyroidism 
• pH is a major determinant of thyroxine fate in multiple metabolic step and even in the 
absorption of oral thyroxine 
• The most frequent conditions that must be taken into account are Helicobacter pylori 
infection, lactose maldigestion and celiac disease 
• Unawareness of thyroxine malabsorption cause may lead to repeated adjustments of dose 
and monitoring 
• The individualization of treatment helps in detecting gastrointestinal malabsorption of 
thyroxine  
• The schematic diagnostic workup to detect gastrointestinal disorders should start based on 
the clinical features and the prevalence of gastrointestinal disorders 
• Thyroxine treatment may be used as a tool to reveal occult gastrointestinal diseases  
INTRODUCTION 
The efficacy of a drug depends on several factors including the appropriate dose, mode of 
ingestion, absorption and potential interfering factors (1-4). This is particularly true for drugs 
with a narrow therapeutic index, which means significant variations of effectiveness for small 
variations of dose (5). Thyroxine (T4) is one such drug with its treatment having been 
significantly changed over the years, based on the availability of more sensitive indexes of 
efficacy (2).  The availability of more sensitive TSH assays, in fact, led to a progressive 
general reduction of thyroxine dose for both replacement and TSH suppressive purposes (2). 
A significant reduction of the harmful effects of both under treatment and overtreatment has 
been observed over the years (1, 3, 6), with particular emphasis on thyroxine treatment during 
gestation (7), at doses that are adequate for both the fetus and successful progression of 
pregnancy. The continuous search for an optimal daily thyroxine replacement has led to the 
1.6-1.8 µg/Kg body weight/day consensus dose, a posology that is able to restore TSH into 
the normal range in most hypothyroid patients (4). However, the number of interfering issues 
rendered often inadequate for a patient a dose that is satisfactory for another (8). It has been 
reported that 20% to 50% of patients fail to show a complete chemical and/or clinical 
response to a reference dose of thyroxine (9). The consequence of that is the need for an 
increased dose, care and monitoring (10). The resulting repetition of unnecessary diagnostic 
workup represents a substantial hidden cost for the national health systems. So far, several 
psychological, nutritional, and pharmacological events may be responsible for the increased 
requirement for thyroxine in these patients (see 2-4, 11-13 for reviews) with some of such 
events deserving mention. Because of poor compliance with the prescribed regimen, certain 
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patients do not take thyroxine regularly, a condition known as pseudomalabsorption (14) and 
once reputed to account for most of the increased requirement of thyroxine. Thyroxine dose 
has to be sometimes increased when different T4 preparations are available and a patient 
switches one to another (see 2 for review). Once pseudomalabsorption has been excluded, 
impaired intestinal absorption of thyroxine caused by nutrients, drugs and gastrointestinal 
disorders represents a major cause of refractory hypothyroidism. In the era of precision 
medicine (15), treatment should be highly individualized and all the characteristics of a drug 
should be taken into account during a chronic and sometimes lifelong treatment. 
In this review we aimed at examining the pharmacologic features of thyroxine 
preparations, and their linkage with the clinical evidence of a reduced intestinal absorption of 
the hormone. 
How the pharmaceutical forms of oral thyroxine are prepared. 
   Typically, leaflets of medicines and websites of drug companies fail to give technical 
information on manufacturing of their products, and thyroxine makes no exception. In 
general, tablets, which are most often disc-shaped, are a solid dispersion of the active 
ingredient and disintegrable excipients, pressed or compacted from a powder into a solid 
dose. Excipients have several functions, and the same excipient may serve more than one 
function (Table I) (16). Examples of such functions are to improve powder flowability 
(gliding), to favor cohesion of different substances (binding), to facilitate tablet disintegration 
in the gastrointestinal tract or to prevent the tablet from sticking (lubrication) (17). To ease 
swallowing and to resist to environmental conditions, the tablet is coated with a polymer. 
Examples of glidants are magnesium stearate and talc; examples of binders are lactose, 
starch, cellulose or polyvinyl pyrrolidone; examples of disintegrants are poly vinyl 
pyrrolidone or sodium carboxymethyl cellulose (croscarmellose sodium); examples of 
lubricants are talc, silica or magnesium stearate (16, 17). Clearly, these ingredients must be 
granulated prior to compression to assure even distribution of the active ingredient and to 
contain the appropriate amount of active ingredient in each tablet (17). In one report (18), 
some intolerance to the excipients used to prepare tablet thyroxine has been observed. 
Recently refractory hypothyroidism linked to improper storage of T4 tablets has also been 
shown. This suggests that in addition to proper mode of ingestion, patients should be 
instructed on proper modalities of thyroxine storage, as well (19). 
    As summarized elsewhere (20), softgel capsules are composed by an outer gelatin 
shell and by a fill formulation, and the highly specialized manufacturing process is divided in 
five different steps. In the sole T4 softgel capsule available thus far, T4 is first dissolved in 
glycerine and then injected into a gelatin shell. This outer shell protects the active ingredient 
from degradation.  
The brand liquid preparation of T4 was a 20 ml bottle containing 100 µg/ml sodium T4, 
being each ml equal to 28 drops, and each drop containing 3.57-µg sodium T4 (21). Drops 
are to be dissolved in water and swallowed. Excipients are ethanol and glycerol (21). 
Noticeably, the Food and Drug Administration (FDA) approved an alcohol-free oral solution 
in February 2017. Bernareggi et al (22) demonstrated the stability of this T4 oral solution 
when added to breakfast beverages. The bioequivalence of these alternative thyroxine 
formulations has been accurately described (21, 23). Concerning tablet T4, which represents 
the choice treatment of hypothyroidism worldwide, there was a concern about switching 
between brands, from a brand to a generic preparation and from a generic to another generic. 
In 2008, the Endocrine Society has published a position statement on this issue to ensure 
pharmacologic homeostasis of patients (https://www.endocrine.org/advocacy/priorities-and-
positions/bioequivalence-of-sodium-levothyroxine). There is, however, general consensus 
that switching between different tablet T4 preparation should be avoided (2, 9).    
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How oral thyroxine is ingested 
Thyroxine tablet is the most used preparation to treat hypothyroidism worldwide (1, 2). 
Patient’s compliance is, of course, a key factor for the proper achievement of thyroxine 
therapeutic goal. Nonadherence to medications is a major challenge in the management of 
thyroxine treatment. When patients do not take T4 regularly, or do not comply with timing in 
relation to food ingestion, and fail to report such behaviors to the endocrinologist, the 
clinician may wonder about the cause of a persistently elevated TSH, despite a high T4 dose 
(14). The term T4 pseudomalabsorption has been used to describe this specific situation. 
Initially the clinician might suspect a decreased T4 gastrointestinal absorption (24), and an 
evaluation for diseases causing malabsorption, or drug interaction should be performed. 
Some authors suggest that an oral T4 absorption test (by giving a total amount of 600 to 
2,000µg of thyroxine ) could be used to demonstrate pseudomalabsorption (4, 25, 26). 
The tablet formulations of levothyroxine contains a stable salt, sodium T4, together with a 
variety of excipients (27). After ingestion, a dissolution phase of the tablet is necessary for 
the subsequent intestinal absorption and, in the dissolution phase, a near physiologic gastric 
pH is required (28). After dissolution, and disregarding a hypothetical minimal absorption in 
the stomach, T4 is essentially absorbed in the small intestine (29, 30). Wenzel et al. (31) 
showed that the absorption of T4 is significantly reduced if the drug is taken after a meal. 
Indeed, it has been shown that certain foods or drinks (such dietary fibers, soybeans, coffee, 
or papaya, etc.) (32-35) reduce the absorption of T4. In addition, nonfasting regimens of T4 
administration are associated with higher and more variable serum TSH concentrations (36). 
Under fasting conditions (in euthyroid subjects), the unidirectional absorption of thyroxine or 
peak values of T4 absorption (Cmax), occurs in the first 90 minutes following T4 
administration, with a rapid increase in the first 60 minutes (37). The time to reach the 
maximum concentration (Tmax) of T4 is about 2 hours after T4 ingestion. Shortly after, 
absorption starts to plateau (37, 38). On the average, 60-80% of ingested T4 is absorbed and 
rendered bioavailable, the distribution volume of the hormone averaging 11.5 liters) (37). 
However, in a study on hypothyroid subjects the Tmax and distribution volumes were 3 hours 
and around 15 liters, respectively) (38). After a meal, the Cmax is decreased and Tmax is 
delayed, with resulting decreased T4 bioavailability. If food, is not postponed by at least one 
hour following T4 ingestion, delayed and decreased intestinal absorption of T4 may follow 
(37). However, bedtime intake of T4 significantly improved thyroid hormone efficacy, 
probably because the lower intestinal motility at night increases the exposure time of 
thyroxine to the intestinal mucosa (39) or because of a better patient’s compliance with the 
treatment (40). Based on these results, postponing breakfast by one hour after ingestion of 
T4, has been suggested in different studies (28, 36, 40) to warrant an efficient absorption of 
thyroxine and to carry out properly studies on malabsorption (41). In fact, in the latter studies 
the daily dose of thyroxine required to obtain a serum TSH <0.5 and 2.5> mU/L was 1.3 
µg/kg body weight (42, 43). This dose is significantly lower than the one recommended by an 
ad hoc ATA task force (1.6-1.8 µg/kg body weight) in adult patients with minimal 
endogenous thyroid function (4). In spite of these studies, leaflets of this hormone still 
indicate a lag time of 30’between the morning ingestion of thyroxine and breakfast, and the 
same interval, it is commonly recommended by the prescribing physicians. Weekly tablet T4 
administration has been also proposed (44), suggesting that auto regulatory mechanisms may 
maintain near-euthyroidism. However, for complete biochemical euthyroidism, a slightly 
larger dose than 7 times the normal daily dose may be required (44). Nowadays, weekly 
tablet T4 administration is used only to detect non-adherence to treatment.  
How oral thyroxine is absorbed 
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The daily dose required to obtain the therapeutic effect is not a linear function of the ingested 
dose of thyroxine, which is the main, but not the only decisive event. Various studies since 
1933 investigated the percentage of oral thyroxine absorbed in man with different techniques: 
single isotope in feces, plasma and liver, double isotope, or using stable T4 and calculating 
the maximum increment in serum T4 or the AUC after serial plasma T4 measurement (45). In 
these studies, in which patients had been treated with different dosage and vehicle of oral 
thyroxine, the percentages of thyroxine absorbed had been estimated between 17 and 93% of 
the ingested dose with an overall value of 60-80% confirmed in a study published in 1991 
using 131-I labeled thyroxine in 3 volunteers (mean value=71±3%) (30). These data have 
been confirmed, also using non-labeled T4, by more recent studies (37). This value seems to 
be increased in patients with overt hypothyroidism; however, this is still a debated issue (38, 
46). Some life conditions may be associated to variations in the absorption rate of thyroxine. 
In particular, during pregnancy, the rise in progesterone leads to delayed gastric emptying 
and prolonged small bowel transit time, by ~30–50% (47). This change may contribute to the 
overall increased need for thyroxine during pregnancy (48). Also in the geriatric age, the 
absorption of T4 seems to be slightly reduced. In fact, it has been shown a decrease of tablet 
T4 bioavailability of about 4% by 10 years of age increase, suggesting that the percentage of 
T4 absorption is decreased in the elderly (49, 50). However, this issue has been recently 
questioned in an extensive study which failed to identify an effect of age on thyroxine 
requirement suggesting that the decrease in lean body mass observed in elderly may be more 
likely responsible for these age-related changes in levothyroxine pharmacokinetics (51). 
Levothyroxine sodium is absorbed along the whole small intestine with different 
percentages in its different segments: it has been shown that the mean values of labeled 
thyroxine absorption were 15±5% in the duodenum, 29±14% in upper jejunoileum and 
24±11% in lower jejunoileum. (30). A concomitant study of the mean transit time in the 
gastrointestinal tract revealed that it was 35±30 minutes in the stomach, 7±3 in the 
duodenum, and 31±8 in the upper jejunoileum. The time between the oral intake and the 
appearance in the plasma seems to minimize the possibility of T4 absorption in the stomach. 
Once ingested, levothyroxine sodium in tablet formulation undergoes disintegration, 
deaggregation and dissolution in gastrointestinal fluids (52): prerequisite for the successive 
absorption, in fact, is that active ingredient is in aqueous solution.  Main factors affecting 
these processes are gastric juice pH and viscosity, type of excipients and structure, shape and 
dimension of active ingredient particles (53).  Furthermore, to ensure molecule stability and 
higher aqueous solubility the pharmaceutical form is the sodium salt of levothyroxine: at 
25°C, the aqueous solubility decreases as pH increases from 1 to 3, then reaches nadir values 
for pH between 3 and 7 and then increases again for pH higher than 7 (54). Recently, a study 
about crystalline conformation of sodium levothyroxine molecule revealed that it may exist in 
different polymorphs (different molecular conformation in the crystal form) which solubility 
changes at different pH values enlightening a possible role of the different molecule 
conformations on T4 solubility (55). In the Biopharmaceutics Classification System, 
levothyroxine is recognized as a Class III drug, i.e. a high solubility drug with a low intestinal 
permeability (56). However, it is important to underline that the solubility of a drug is tightly 
related to the pharmaceutical formulation and may vary among the different preparations 
(57).     
Transport of thyroxine across the intestinal mucosa 
In the early ‘60s, it was believed that the transport of thyroxine inside cells occurred through 
passive diffusion mechanisms based on the high lipophilicity of the molecule (58). Since 
then, evidence have changed our understanding on the mechanisms underlying thyroxine 
transport. First of all, thyroxine is an amphipatic molecule with a lipophilic aromatic ring and 
a hydrophilic side chain and possess three ionizable moieties, two acidic (phenolic -OH, and 
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carboxyl -COOH) and one basic groups (amino -NH2). The relative dissociation constants are 
6.71, 2.04 and 8.85, respectively (59) (Figure 1). Furthermore, it has been enlightened that at 
different pH, thyroxine molecule may exist at eight different micro species (60). In addition, 
it has been reported that the paracellular route of absorption may show only a negligible 
contribution for compounds larger than molecular weight of 250-300 D (61) and thyroxine is 
774 D. For these reasons, iodothyronines are trapped and not be able to cross the lipid bilayer 
in the absence of specific carriers (62) and become constituents of the cell plasma membrane 
in vertebrates (62). Besides the amphotericity of the molecule, further hindrance to diffusion 
through the plasma membrane comes from the charge of thyroxine. In fact, in aqueous 
solution, thyroxine exists predominantly in ionized form and in particular in zwitterionic 
form (OH, NH
 3 
+
, COO-) in the range of pH between 2.46 and 6.91 and in monoprotonate 
form for more basic pH (O-, NH3+, COO-) while the cationic and anionic forms predominate 
at extreme pH (63). As a matter of fact, the pH-partition hypothesis postulates that “the 
absorption of ionizable drugs mainly takes place in compartment(s) where the local pH 
ensures a sufficient concentration of the non-charged form relative to the ionized form(s)” 
(64).   Nowadays, therefore these finding indicate the passive diffusion as a residual transport 
route (65). 
Over time, studies have focused on the presence of specific carriers that facilitate the 
passage of thyroid hormones through the cell membrane. Different categories of transporters 
may act as T4 carrier the level of small intestine: monocarboxylate transporter (MCT) family, 
organic anion-transporting polypeptide (OATP) family, ATP-binding cassette (ABC) 
transporter superfamily and large neutral amino acid transporter (LAT) family (66). 
Two MCT involved in thyroxine transport have been identified in the small intestine 
mucosa: in fact, MCT8 and MCT10 mRNA are expressed in both stomach and small intestine 
human mucosa (67). Both these transporters are constituted by 12 transmembrane domains 
with the amino- and carboxy-terminal intracellular domains, showing a high degree (49%) of 
homology of the amino acid sequence (65). Both the transporters are responsible for cellular 
influx and efflux of T4 (68). MCT8, the primary transporter of TH, is expressed in many 
tissues but its activity is mainly devoted to TH transport across the blood brain barrier and to 
the development of human brain, as proven by neurological deficits in patients with MCT8 
gene mutations (69). A specific localization of MCT8 in human intestine has not been 
identified and the possible functions have not been extensively studied yet. However its 
involvement in T4 transport has been suggested by the increased need for thyroxine observed 
in athyreotic patients treated by sunitinib and imatinib which non-competitively inhibited this 
transporter in vitro perhaps by a direct binding (70). On the contrary, MCT10 is highly 
expressed at small intestine level and in particular in the basolateral membrane of mucosal 
cells leading to the hypothesis of its possible role in the intestinal T4 resorption (65). Some 
members of the organic anion-transporting polypeptide (OATP) family, able to transport T4 
have been identified in small intestine. OATP1A2 has been identified in the apical brush 
border of duodenum enterocytes but in a small quantity (71, 72). This transporter carries a 
wide spectrum of substances in a Na+ and ATP-independent way (73), but its activity may be 
sensitive to medium pH (74). The study of the interferences on the OATP1A2 activity 
allowed defining its importance for the transport of different compounds including thyroxine: 
in particular, flavonoids as naringin and hesperidin, component of grapefruit and orange 
juice, respectively, may interfere with OATP1A2 (75). A study on the effect of naringin on 
OATP1A2 showed that its effect in reducing oral availability of these transporter substrates 
(i.e. thyroxine, acebutolol, fexofenadine etc.) lasted 2 to 4 hours. The extent of that effect was 
different for each substrate and more pronounced if the drug is hydrophilic and excreted 
unchanged and less when lipophilic and largely metabolized (75). It is not surprising that 
inhibition of OATP1A2 had only a minimal effect on AUC of thyroxine (35). The authors 
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postulated an effect on T4 elimination from enterocytes, and not on T4 absorption, that may 
impair the hormonal enterohepatic recycling and thus bioavailability (35). The evidence that 
β-blockers and tricyclic antidepressants may use this same transporter shed light on a novel 
site of interaction with thyroxine (76).  A similar involvement in the process of recycling of 
thyroid hormones from ileum to the liver has been proposed also for OATP4A1, through the 
portal vein (77). In a recent study, Meyer Zu Schwabedissen et al (78) have studied the role 
of OATP2B1 in contributing to intestinal thyroxine absorption. They concluded that thyroid 
hormones are in one time substrates and transcriptional regulators of this transporter in 
enterocytes (78). P-glycoprotein is a membrane protein that belongs to the superfamily of 
ABC carriers that transports mono-directionally multiple substrates including thyroxine out 
from cells (79, 80). The inhibition of this protein seems to be related to the increased AUC of 
levothyroxine when co-administered with rifampin (81). LAT1 transporter, that when 
associated with CD98 transports T4, has also been detected in Caco-2 cells, a model 
expressing many morpho-functional characteristics of the absorbent epithelium of the small 
intestine (82). However, the rate of thyroxine uptake was low (83). Overall, the existence of a 
main or thyroxine-restricted transporter at the intestinal level is still an unanswered question. 
Moreover, it appears that substances and drugs impairing the activity of known intestinal T4 
transporters mainly interfere with the outflow of the hormone from the enterocyte and with 
the enterohepatic recirculation of T4. In fact, once absorbed in the small intestine, thyroxine 
reaches the target organs where its peripheral metabolism takes place. Beyond deiodination, 
there are also alternative metabolic pathways as extensively reviewed by Visser et al. (84) 
and Wu et al (85). In the liver, thyroxine and triiodothyronine are conjugated with sulfuric 
and glucuronic acid which makes them more soluble, allowing their renal and biliary 
clearance (84). The presence of the intestinal microbial flora allows the binding of 
iodothyronine, thus creating a hormonal reservoir (85); on the other hand, due the presence of 
sulfatase (86) and glucuronidase (87) activities in the intestinal contents, intestinal microbiota 
help their deconjugation and the possible hepatic reuptake through the portal circulation. 
Changes in the intestinal microbiota, known as dysbiosis, may therefore be responsible for 
variation in these metabolic steps (88, 89).  
Gastric disorders affecting thyroxine absorption  
Plenty of conditions, either physiological, nutritional, pharmacologic or pathologic, may 
impair the intestinal absorption of oral levothyroxine (2, 3). However, an increased need for 
thyroxine not necessarily indicates gastrointestinal malabsorption of the hormone. Whether 
the serum TSH would be a reliable marker of hypothyroidism is still a debated issue (2, 90). 
However, in clinical practice, serum TSH levels is, yet, the easier and faster diagnostic tool to 
evaluate thyroxine treatment effectiveness (1, 2, 4).  
In the past, the uncertainty about the appropriate thyroxine dose for the treatment of 
hypothyroidism, for both the general population and its relevant subclasses (i.e. children, 
adult, elderly persons, obese, pregnant, polypharmacy, thyroidectomized) did not help to 
focus on thyroxine malabsorption. The more recent efforts to standardize T4 treatment (see 1, 
2, 4 for rev) and the seminal paper from Santini et al. (91), indicating that the dose of 
thyroxine is dependent on lean body mass, opened the door to more precise posology of 
thyroxine dose.  Nowadays, the use of an individually tailored dose of T4 is advised to detect 
an increased need for thyroxine (41, 92 abstract).  
Since there is no evidence that thyroxine may be significantly absorbed in places other 
than in intestinal sites, the observation that in patients with impaired gastric acid secretion a 
higher dose of T4 would also be required, widened the research on thyroxine malabsorption 
mechanism (28). Possibly confused with pseudomalabsorption in the past, the gastric-related 
malabsorption of levothyroxine represents nowadays an increasingly recognized issue in a 
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relevant number of hypothyroid patients (41). The acid producing machinery (i.e. the H+/K+ 
ATPase) is located in the oxyntic glands in the gastric fundus and its action is enhanced by 
the production of gastrin from the antral G cells) (93). Acid production is partially or totally 
abolished in patients with chronic gastritis and/or gastric atrophy (94), is blocked in those 
treated with proton pump inhibitors (PPI) (93) as well as partially blocked and counteracted 
by NH3 production in patients with Helicobacter pylori infection (95, 96). All these 
conditions have been related to increased thyroxine requirement (3, 28, 97, 98) (Figure 2).  
Evidence in vitro and in vivo highlighted this novel role for the stomach in the subsequent 
intestinal T4 absorption (41, 99). In vivo, the role of gastric acid secretion has been 
demonstrated in treated goitrous patients with an impaired gastric acid secretion (28). In fact, 
daily T4 requirement was increased by 1/3 in patients with Helicobacter pylori-related 
gastritis, atrophic gastritis and maximal in those with both these conditions (28). In keeping 
with these results, hypothyroid patients with positive anti-parietal cell antibodies (PCA) 
showed an increased daily thyroxine requirement (100). These authors found an increase by 
17% in PCA positive as compared with PCA negative patients and such an increase was even 
higher (+32%) in those patients with proven atrophic gastritis. In thyroxine-treated patients 
with recent H. pylori infection a significant TSH raise has also been observed. Such an effect 
was counteracted by increasing the dose of thyroxine, being only partially reversed by 
Helicobacter pylori eradication (28). Eradication of this infection, in fact, does not always re-
establish the previous conditions of the mucosa, as an antritis or even a pangastritis may 
ensue with a possible evolution to gastric atrophy (101). Helicobacter pylori infection affects 
30-to 50% of general population worldwide (102) and the high prevalence of this sole 
disorder may potentially increase the need for thyroxine in a higher number of patients than 
in those with supposed pseudo-malabsorption. 
Drugs interference at gastric level 
A third way to impair the gastric acid secretion is the treatment with PPI. Firstly, the effect of 
omeprazole on thyroxine needs has been described in goitrous patients in whom the 
concomitant use of these two drugs significantly increased serum TSH (28). The effect was 
reversed by increasing the dose of T4 by 37% or by discontinuing the use of PPI. Similar 
results were obtained by Sachmechi et al. (103) using lansoprazole in patients with serum 
TSH >5 mU/l. In contrast, absorption kinetics of high dose of thyroxine seem to be 
unchanged by the concomitant ingestion of pantoprazole and esomeprazole for one week 
(104, 105). However, the effect of PPI on pharmacologic thyroid homeostasis has been 
confirmed by TEARS study (106). Noticeably, very recent data in vivo pointed out that the 
replacement dose of thyroxine is inversely correlated with gastric pH, supporting the 
hypothesis that variations in gastric juice pH, like during PPI treatment, may affect thyroxine 
dose (107). Beside PPI, other drugs seem to interfere in a pH-related fashion with thyroxine 
absorption (antiacids, calcium salts etc.), their effect having been extensively reviewed 
elsewhere (108,109). Despite the adsorption of thyroxine would be the main mechanism of 
interference for most of drugs (108), the role of gastric pH may be relevant for some of them 
(Figure 3). Beside the abovementioned effect of drugs in reducing gastric juice pH, a further 
pH dependent process may occur at gastric level (110). On this ground, the effect of calcium 
carbonate is a model. In fact, Singh and colleagues (110,111) have shown that both acute and 
chronic ingestion of calcium carbonate reduces the bioavailability of T4. A similar 
interference was also evident when using different preparation of calcium (112). In a first 
study (110), a supplementation of 1200 mg/day for 3 months led to a reversible increase of 
serum TSH in 2/3 of patients. Interestingly, in the same paper, a binding study revealed that 
at pH 2, but not at pH 7.4, a significant fraction of thyroxine was adsorbed to calcium 
carbonate in a dose dependent way, preventing the absorption at the intestinal level. In 
addition, this interference with oral thyroxine was confirmed by the evidence that calcium 
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carbonate acutely reduces the main pharmacokinetic parameters of T4 absorption (111). 
Some nutrients seems to act through a similar cooperative mechanism to reduce the 
absorption of thyroxine (113, 114); indeed, the papaya fruit contains proteolytic enzymes, 
including papain, which decreases histamine-induced acid secretion; but author suggested 
that the papaya fibers might also bind thyroxine in the intestine (113). Very recently, Chon et 
al have described that simultaneous milk ingestion decreases oral levothyroxine absorption 
(114). The pH of naïve cow’s milk is around 6.6/6.7 and it contains more than 1 gram of 
calcium per liter, so that is not surprising that the pH sensitive fraction of T4 absorption 
might be affected (114). At the same time, naïve milk contains fat, proteins, lactose that may 
maintain thyroxine in the intestinal lumen preventing its absorption (29,115). 
The overall mechanism by which intestinal absorption of thyroxine may be impaired in 
hypo-achlorhydric patients remains, however, unclear. Iodothyronines are themselves pH-
dependent molecules (54). In vitro studies have been carried out and since 1971 Amirav 
Gordon indicated that blood pH may affect the partition between the intravascular and rapidly 
exchanging pools of thyroxine (116). Centanni M and Robbins J (117) have shown the role of 
pH in thyroid hormone uptake in skeletal muscle and several membrane transporters of 
thyroxine at the intestinal level are sensitive to pH changes (118). Beside the naïve thyroxine, 
the pharmaceutical preparation is also dependent on medium pH.  Pabla and colleagues (99) 
have shown in vitro that the dissolution of tablet thyroxine is over 85% within 20 minutes 
only at low pH (<2.4). According with FDA, this time corresponds to the half-life of fasting 
gastric emptying for rapid release drugs (57).  At increasing medium pH the dissolution of 
tablet T4 rapidly decreases at all times studied (30’, 60’ 120’), while the softgel T4 
preparation seems to be less sensitive to that variable (99). However, the dissolution time 
does not fully explain the subsequent absorption rate. In fact, Kocic et al (119) have shown 
that the dissolution rate and the absorption rate in the first two hours may diverge, indicating 
that dissolution does not greatly influence the absorption of levothyroxine in the period of 
time (1.66 hours) in which the maximal absorption take place (37).  Noticeably, a better 
absorption of thyroxine has been observed in patients simultaneously taking vitamin C (120, 
121) which may lower gastric pH in patients with impaired acid secretion (109). 
So far, it appears that the ionization status of thyroxine is important and that thyroxine 
ionizable moieties are dependent from ambient pH (122). It has been suggested that 
pharmaceutical T4 preparation, a hydrophilic sodium salt, may remain partly undissociated in 
a hypochlorhydric gastric environment and this event may impair the efficiency of 
subsequent intestinal absorption (28). Although the mechanism is not completely elucidated, 
the clinician must be aware of the widespread impact of these interfering conditions because 
of the very high prevalence of H. pylori infection (102) and the prescription rate of proton 
pump inhibitors (123). Therefore, in the past, the studies aimed at identifying an appropriate 
daily T4 dose may have been biased from the presence in the sample of an unknown number 
of infected patients. 
Altered gastric motility and bariatric restrictive procedures 
Gastroparesis is defined as delayed gastric emptying in absence of mechanical obstruction 
and its prevalence is about 0.04% in an area of United States (124). Idiopathic, postsurgical, 
and diabetic gastroparesis are the most frequent forms. Only few case reports deal with the 
correlation between gastroparesis and thyroxine absorption (125, 126). The first one 
described an old man with persistent hypothyroidism despite a high thyroxine dose (>2.7 
mcg/Kg/day). In this case, upon the exclusion of the main causes of thyroxine malabsorption, 
the diagnosis of gastroparesis had been confirmed by gastric emptying study (125). In the 
second report, in a pregnant hypothyroid young female with type 1 diabetes, gastroparesis has 
been diagnosed (126). In this study, the link between T4 malabsorption and gastroparesis has 
been confirmed by a faint response of FT4 during T4 absorption test. On the contrary, the 
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weekly intramuscular injection of T4 led to the improvement of the thyroid hormonal profile. 
In addition to gastroparesis itself, the residual food in the patient’s stomach, that may adsorb 
the ingested T4, might represent a further mechanism of malabsorption (31, 126). In this 
patient, the refractoriness to oral thyroxine treatment worsened during the pregnancy because 
of, besides diabetic gastroparesis, an even slower gastric motility, might be induced by 
progesterone (127). Reardon and Yoo (128) also reported a better performance of softgel 
thyroxine preparation in a hypothyroid patient with gastroparesis, who quickly corrected her 
thyroid function by using that formulation of thyroxine. A recent case report suggested that 
the motility of the whole gastrointestinal tract may affect thyroxine bioavailability (129). In 
fact, a severe refractory hypothyroidism was associated with systemic sclerosis, a chronic 
disorder characterized by muscular atrophy and fibrosis of gastrointestinal tract. In this case, 
the esophageal sclerosis reduced esophageal motility impairing the bolus progression of 
thyroxine (129). Authors suggested that the severe hypothyroidism was due to reduced 
thyroxine absorption, since TSH was progressively normalized upon switching to a liquid 
formulation of thyroxine.  
As far as concerns the bariatric procedures involving gastric restriction (gastric banding 
and sleeve gastrectomy), they are considered procedures that alter drug absorption less than 
procedures involving intestinal diversion (130). The two mechanisms involved are the drug 
disintegration and the drug dissolution: the first step is necessary for a drug to become 
soluble with the gastrointestinal milieu and is the rate-limiting step in the absorption of most 
solid drug form because the gastric mixing promotes drug disintegration (52, 53). In sleeve 
gastrectomy a substantial part of the gastric fundus and body, the areas of the stomach 
containing most of the acid-producing cells, is removed. Therefore, the gastric pH increases 
and the solubility of some drugs would be reduced (130). Despite an expected increased need 
for thyroxine following bariatric surgery, the data are conflicting. Pharmacokinetic 
parameters of levothyroxine were, in fact, not decreased but rather increased in obese 
euthyroid patients before and after sleeve gastrectomy and gastric bypasses (131). In this 
study, however, the patients underwent thyroxine absorption test with an oral solution of 
levothyroxine that does not require the gastric dissolution (131). Aggarwal et al (132) have 
analyzed 19 hypothyroid patients that underwent sleeve gastrectomy and demonstrated that 
13/19 patients improved their thyroid status with a lower dose of thyroxine, showing a 
correlation between percent excess of weight loss and the change in thyroxine dose. On the 
contrary, Sundaram et al (133) and Fierabracci et al (134) demonstrated a decrease or no 
change in total thyroxine dose but an increase of weight-based levothyroxine requirement, in 
patients after sleeve gastrectomy or gastric banding. To explain these contrasting results, 
authors have suggested time by time accelerate gastric emptying, modified gastrointestinal 
motility, alterations in bile acid and in gut microbiome composition without consistent data. 
The changes in lean body mass following bariatric surgery could also potentially contribute 
to a change in LT4 doses (91). In fact, only weight-based evaluation may lead to reliable 
results. Therefore, according to Gadiraju et al. (135), further controlled studies are needed 
before drawing definite conclusions.  
Intestinal  disorders IMPAIRING thyroxine absorption  
Celiac disease (CD) has an estimated prevalence in the general population of 1% (136) but its 
prevalence rises to 2-5% of patients also bearing a thyroid autoimmune pathology (137), the 
main cause of hypothyroidism. Furthermore, being thyroid autoimmune disease the most 
frequent autoimmune disorder, a definite higher rate of Hashimoto’s thyroiditis may be 
detected in patients with celiac disease than in the general population (138). The joint 
presence of these two diseases is one of the more frequent associations included in the 
polyendocrine autoimmune syndrome type 3 B (PAS 3) (139). The ratio between patients 
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with overt celiac disease and patients in which the disease is present but not diagnosed is 
about 1:8 (140). As celiac disease may also present without gastrointestinal suggestive 
symptoms (CD atypical presentation) (140), its presence should be suspected in hypothyroid 
patients with an increased need for thyroxine (42). To the best of our knowledge, the 
impairment of oral levothyroxine absorption in a patient with celiac disease has been reported 
since 1993 in a patient with milk protein allergy and celiac disease (141). Later, some case 
reports confirmed the occurrence of resistance to oral levothyroxine treatment in hypothyroid 
patients with celiac sprue (142, 143). In 2012 two studies (42, 144) have deepened the topic 
in 7 patients with untreated celiac disease and in 35 subjects affected by atypical celiac 
disease. In both groups, the gluten free diet reversed the increased hormone needs, only 
partially in the first study (144) and completely in the second one (42). The mechanisms 
leading to the increased need for thyroxine in patients with celiac disease may follow the 
progressive reduction of intestinal surface characterizing the histologic lesions of this disease: 
a) the villous shortening till total atrophy, owing to enterocyte’s apoptosis and to inadequate 
cell regeneration in crypts (145) and b) the significant lymphocytic infiltration. This event, in 
turn, determines the loss of proteins and enzymes in the brush border, thus impairing the 
absorption of a large number of nutrients (146). In CD patients, the extent of impairment of 
drug efficacy may depend on the pharmacokinetic characteristics of each drug (147). In fact, 
beside the reduction of the absorbing surface, the following pathologic characteristics were 
reported in patients with celiac disease: increased intestinal permeability, increased 
gastrointestinal transit time and changes in intestine luminal pH (147, 148). An abnormal 
gastric emptying was even described, perhaps depending on an altered secretion of 
cholecystokinin and plasma polypeptide YY, hormones involved in the gastrointestinal 
motility (148). An increased prevalence of bacterial overgrowth in the small intestine has 
been also observed, usually in patients with clinical persistence of symptoms, even after 
removal of gluten from the diet (149). Similar to other nutrients and drugs, all these 
mechanisms may contribute to thyroxine malabsorption.   
Lactose maldigestion is a condition, mostly symptomless, to which about 70% of adult 
human beings (lactase non persistent) is exposed (150). This condition is caused by the 
decline in residual lactase activity, due to the down regulation of the enzyme responsible for 
the hydrolysis of lactose to glucose and galactose (150). Lactose intolerance (LI), has instead 
a pleiotropic clinical picture, presenting with diarrhea, bloating, flatulence, abdominal pain, 
the intensity of them being related to: a) the amount of lactose ingested; b) intestinal 
microbial composition; c) gastrointestinal motor activity and, finally, d) the visceral 
sensitivity to fermentation products of lactose digestion (151). Beside the primitive form, 
lactose intolerance may follow any process able to destroy the mucosa of the small intestine 
(CD, infections, surgery, etc) (152, 153). At first, Muñoz-Torres (154) described a case of 
one patient showing an increased need for thyroxine induced by lactose intolerance, resolved 
by switching to lactose-free thyroxine formulation and starting a lactose free diet. A similar 
effect was observed following 8 weeks of lactose restriction confirming that lactose-free diet 
may improve thyroid pharmacologic homeostasis in patients with LI (155). Later, a 
systematic study confirmed the increased need for thyroxine in a larger group of patients with 
LI, as compared with a control group without signs or symptoms of malabsorption 
(+31%)(43). More than a mechanism may explain the effect of lactose intolerance on the 
need for thyroxine. When the hydrolysis of lactose does not take place, this sugar 
accumulates and attracts water in the intestinal lumen (151). Thus, an altered intestinal 
content may complex with thyroxine preventing absorption (43), or may even increase the 
intestinal motility, thus reducing the exposure of thyroxine to the absorbent surface (156). 
Moreover, LI is often associated with the small intestine bacterial overgrowth (SIBO) (157) 
which may also impair the enterohepatic recycling of thyroxine.                
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Lactose is also used as an excipient in some drugs and in some formulation of tablet 
thyroxine, and the amounts is not often disclosed in the leaflets (27). This fact led to the 
suspicion that lactose content in these thyroxine preparations may represent a problem: a 
study, however, provided evidence that ingestion up to 400 mg of lactose does not trigger 
gastrointestinal symptoms nor affect the lactose breath test (158). Noticeably, gastrointestinal 
symptoms are usually evoked by quantities greater than 5 g of ingested lactose (159). 
Therefore, the possibility that a very small amount of the disaccharide in the thyroxine tablet 
might be responsible for its malabsorption is unlike.  
The parasitic infestation from Giardia lamblia (GL) has also been considered as a cause 
of thyroxine malabsorption. This parasitism is sporadic in Western countries where it seems 
more frequent in travellers (160). On the contrary, this flagellate protozoan is usually 
endemic in environments characterized by poor sanitary conditions (161). Clinical 
manifestations range from severe gastrointestinal derangement to asymptomatic forms (162). 
Only two case reports described an increased need for thyroxine due to the GL infestation 
(163, 164), both describing an elevation of serum TSH and an increased need for thyroxine 
that were reversed by appropriate antiparasitic treatment. The cause of thyroxine 
malabsorption in these patients is the inflammatory mucosal damage and epithelial apoptosis 
induced by the protozoan (165); furthermore, in these patients an increased intestinal 
permeability may be observed, due to the disruption of the intestinal tight junctions (166).  
Besides the disorders directly affecting the absorbent mucosa, also diseases affecting 
organs involved in the digestion process may impair oral thyroxine efficacy. Indeed, 
pancreatic insufficiency may cause steatorrhea following the reduction of lipase secretion 
below 10% of normal levels (167). In an early paper on eight patients published in 1962 
(168), the authors observed that pancreatic steatorrhea increased the elimination rate of the 
hormone, showing that fecal losses of the hormone were higher than normal. They 
hypothesized a defective hydrolysis of glucuronated thyroxine that impaired the enterohepatic 
circulation in these patients. A direct interference with compounds usually degraded by 
pancreatic enzymes, resulting in an organic iodine adsorption in the intestinal content was 
also suggested (168). Cystic fibrosis that frequently leads to pancreatic insufficiency has been 
reported as a cause of decreased thyroid hormone absorption (169). Furthermore, a recent 
paper described two cases in which an increased need for thyroxine has been shown in 
patients bearing liver cirrhosis (170). The authors speculated that the impaired bile secretion, 
besides the variation in Tiroxine Binding Globulin concentration, might explain this effect. 
On the same line, a paper by Sinha and Van Middlesworth (115) underlined the role of bile in 
reducing the binding of thyroxine to intraluminal plasma proteins, thus increasing the 
absorption of labeled thyroxine in a washed jejunal loop of rats. The authors postulated the 
presence in the bile of substances competing for T4 binding with plasma proteins (115).  
In a previous section we have described the putative mechanism of thyroxine absorption 
at the small intestine level; the effect of the short bowel syndrome (SBS) on thyroxine 
absorption has been investigated since ‘80s (171, 172). This disease is usually the 
consequence of congenital malformations or acquired diseases that require surgical resection 
of small intestine, thus causing the reduction of intestinal absorptive surface along with 
motility disturbances (173). Moreover, the absence of last ileal loop and of ileo-cecal valve 
may lead colonic bacteria to rise in the residual small intestine prodicing a dysbiotic 
environment dominated by Lactobacilli (174). The study of radiolabelled thyroxine 
absorption in five patients with SBS as compared to two healthy subjects, revealed a net 
reduction of oral thyroxine absorption, independently from the lengths of intact bowel (171). 
It has been suggested that, beside the shortened intestinal surface, a key role in determining 
T4 malabsorption in these patients may be played by the accelerated intestinal transit (175). 
Bariatric surgery 
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On a similar ground, the interference on thyroxine absorption exerted by bariatric surgery 
including intestinal bypass has been extensively analyzed, although with conflicting results 
(see above for bariatric surgery involving only the stomach).  The three case reports about the 
effects of jejunoileal bypass technique consistently reported a significantly (from three to four 
fold than normal dose) increased T4 need, again suggesting the role of a reduced absorptive 
surface (176-178). This technique has been next abandoned because of the association with 
multiple severe short- and long-term complications. Nowadays, most of the paper published 
on this topic examined the need for T4 in patients who underwent Roux-en-Y gastric bypass 
(RYGB), a common procedure nowadays. By examining 23 patients, Raftopuolos et al. 
observed that 13 of them maintained the same daily requirement while eight showed a 
reduction of the dose (179). However, as mentioned above, Sundaram (133) and Fierabracci 
(134) described that, when normalized by weight, an increased thyroxine dose is necessary to 
achieve target TSH levels in most of these patients. These results are in keeping with the 
increased TSH values observed in patients treated with the same dose of thyroxine before and 
after surgery (180, 181). Two pharmacokinetic studies have been performed to investigate 
this issue (131,182). Despite an improvement of absorption parameters, Rubio et al. (182) 
observed a significant delay of T4 absorption in the surgical-treated patients. In the 
previously mentioned study (131), the pharmacokinetic parameters were similar before and 
after RYGB surgery. This latter study also examined 15 patients who underwent 
biliopancreatic diversion observing an improvement of thyroxine pharmacokinetic parameters 
(131). However, Fallahi et al (181), by using the same dose of tablet formulation of thyroxine 
before and after the surgery, observed that serum TSH  worsened after surgery. While the 
results in patients exclusively treated with malabsorptive procedures agree to identify a clear 
increase in thyroxine requirement, results about thyroxine need in patients treated with 
procedures combining restrictive and malabsorptive techniques are conflicting. This may 
depend on the different schedule of thyroxine ingestion (often omitted) (i.e. lag time between 
food and therapy or other drugs) and on the diverse effects that surgery may have on patient’s 
gastrointestinal physiology (i.e. altered gastric juice acidity, dumping syndrome, delayed 
gastric empting, different gut microbial flora, variations of lean and fat body mass ratio, 
etc)(183, 184). Moreover, the assessment of thyroxine needs not always normalized by 
weight does not allow a correct and complete comparison of the data. The heterogeneity of 
these studies in patient underwent bariatric surgery with mixed restrictive and malabsorptive 
techniques does not allow to draw definitive conclusions about the net effect on thyroxine 
requirement.  
Nutrients and food interference 
In 1977, using a double isotope method, Wenzel and Kirschsieper (31) clearly demonstrated 
that fasting condition ensures a better thyroxine absorption than in a feeding state. Over time, 
several papers have examined the interference exerted by different kinds of foods on the steps 
that bring to levothyroxine absorption.  
As early as 1957, van Middlesworth (185) reported that cellulose- or bran-rich chow 
leaded to increased fecal loss of thyroxine in rats. In 1996, Liel et al (186) demonstrated a 
nonspecific, dose dependent adsorption of the hormone by wheat bran in vitro.  This may 
explain the clinical findings of an increased need for thyroxine in 13 hypothyroid patients 
who had increased their fiber intake (186). On the contrary, a succeeding pharmacokinetic 
study in 8 healthy volunteers did not confirmed a variation in the absorption rate of thyroxine 
ingested with calcium polycarbophil or psyllium hydrophilic mucilloid (187). The possible 
interference of fibers on the enterohepatic recycling of thyroxine more than a direct effect on 
absorption has been suggested (188, 189) and may help to interpret these data. In fact, a 
similar mechanism has been postulated for the interference exerted by soy ingestion in 
thyroxine treated patients. In this first report in humans by Pinchera et al. (190), an athyreotic 
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cretin, fed soybean formula, showed a refractoriness to high doses of desiccated thyroid. 
Additional evidence were an increased fecal concentration of thyroxine and a higher fecal 
mass, so that they hypothesized an intestinal dysbiosis as a further cause of intestinal trapping 
of thyroxine (190, 191).  Several studies on this topic have confirmed the effect of soy 
formula in hypothyroid infants (192-194) and one study reported a similar effect also in a 
thyroidectomized woman using soy protein supplement (195). In this latter case report, the 
efficacy of thyroxine treatment has been regained separating thyroxine from soy ingestion by 
12 hours. A very recent pharmacokinetic study, performed in 12 patients on stable thyroxine 
treatment, demonstrated that bioavailability of thyroxine is superimposable in patients co-
ingesting a fixed combination of soy isoflavones or with a six hours interval (196). A case 
report also described the impairment of pharmacological thyroxine homeostasis in a 
thyroidectomized patient after two weeks of large amount of papaya fruits consumption 
(113). After discontinuation of papaya consumption, the patients recovered the euthyroid 
state without increasing thyroxine dosage. Beside the effects on gastric acid secretion (see 
above), the authors hypothesized an effect on intestinal motility of a component of the fruit 
and an action on deconjugating bacterial enzymes that may increase fecal thyroxine loss 
(113). A brand new paper (114) has directly reported the effect of concomitant 2% fat cow-
milk intake with thyroxine (see above), hypothesizing also an interfering role for milk 
proteins, based on evidence from in vitro studies by Hays (29) and Sinha and van 
Middleworth (115). 
Even the espresso coffee may cause refractory hypothyroidism. The concomitant 
ingestion of coffee was examined in vivo and in vitro by Benvenga et al (33). The 
simultaneous ingestion of coffee and levothyroxine altered pharmacokinetic parameters also 
delaying the time of maximal incremental rise of serum T4. The in vitro study confirmed that 
coffee acts as a weak thyroxine sequestrant (33). The putative effects on thyroxine transporter 
activity by grapefruit juice have been discussed above. 
Drugs interference 
Several drugs interact with intestinal absorption of levothyroxine. In most cases, these drugs 
are able to bind levothyroxine creating insoluble complexes that prevent successive thyroxine 
absorption process but this kind of interaction has not been proven for all of them. Some of 
these drugs seem to affect different steps of thyroxine absorption. Some clinical reports stated 
that aluminum hydroxide, active ingredient of antacid preparations, affects thyroxine 
pharmacological homeostasis (197). In particular, the impact of this drug on thyroxine 
absorption seem to involve both gastric and intestinal processes of absorption. In fact, beside 
the abovementioned increase of gastric pH and the slowing of gastric empting, a nonspecific 
adsorption of T4 in vitro (20% of the 50 mcg in the incubation system were removed by 1 ml 
of aluminum hydroxide) (198) may further hamper oral T4 efficacy. Conflicting results in 
vitro and in vivo where obtained with a further antiacid, sucralfate. In fact, in an early in vitro 
study the binding of thyroxine by sucralfate in gastric acid medium has been shown (199). 
Later on, one pharmacokinetic study, carried out on healthy volunteers, demonstrated that 
sucralfate reduces the maximum T4 absorption of about 70% with a significant delay in the 
absorption process (200). However, two clinical studies failed to confirm these findings (201, 
202). This issue deserves clarification by further studies. On the contrary, the concomitant 
ingestion of ferrous sulfate has been proven to reduce thyroxine efficacy in hypothyroid 
patients (203-205). In fact, an in vitro experiment demonstrated that at pH 7.4 a ferric-ion 
binds three thyroxine molecules in an insoluble complex (203). A seminal paper published in 
1969 (206) demonstrated that also cholestyramine resin, used as a lowering cholesterol agent 
(able to bind bile acids and cholesterol metabolites in the intestinal lumen), is able to bind 
large amount of thyroxine either at a pH 1 or 9 in vitro. By using 131I labeled thyroxine in two 
patients, the authors demonstrated a two-fold increase in stool and a concomitant reduction in 
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urine radioactivity as compared to control values, thus proving a negative effect on thyroxine 
absorption (206). An interval of five hours from levothyroxine to cholestyramine ingestion 
was not at all sufficient to restore thyroxine absorption, and authors suggested that 
cholestyramine may act as an inhibitor of hormonal enterohepatic recycling (206). Because of 
this specific activity, this drug has been also used to treat acute hyperthyroid patients (207, 
208, 209). The ability to impair the pharmacokinetic parameters of levothyroxine has been 
described in two studies for a further bile acid sequestrant, colesevelam (210, 211). This drug 
has been proven to bind thyroxine, in vitro, in an increasing fashion from a medium pH=1,2 
(similar to gastric pH) to pH=6,8 (simulating intestinal fluid) (210, 212). An in vitro binding 
has been proven also for a cation-exchange resin, sodium polystyrene sulphonate (SPS) 
(213). Also this ability of SPS has been proven in both an acidic medium (pH 2) and a neutral 
one: the reduction of dissolved thyroxine in the supernatant was of 93% and 98%, 
respectively. 
For some drugs, despite an in vitro binding study has not been performed, 
pharmacokinetic studies demonstrated a reduction of thyroxine absorption. This is the case 
for ciprofloxacin, sevelamer, chromium picolinate, lanthanum carbonate and raloxifene. 
Coadministration of these drugs with 1000 mcg of thyroxine in healthy subjects decreased the 
T4 AUC from 0 to 6 hours ranging from 17% to 50% as compared with the one observed in 
control test (81, 211, 214, 215). Finally, a possible interference of orlistat (216) and 
simethicone (217) with thyroxine absorption has been only mentioned in case reports.  
The use of malabsorption of thyroxine as a tool to diagnose occult GI disorders 
A tight schedule of thyroxine treatment represents a prerequisite to detect any increased need 
for thyroxine. Patients requiring a higher than expected dose of thyroxine to reach the target 
TSH may be encompassed in the definition “difficult patients” according to Ward LS (218). 
They are exposed to refractory hypothyroidism (3), but not all of them have GI 
malabsorption. Once ascertained the existence of an increased need for thyroxine, physician 
must firstly exclude the pseudomalabsorption, the recent and significant weight, BMI and/or 
body composition variations as well as the possibility of pregnancy. Then a careful nutritional 
and pharmacological anamnesis should be carried out (Figure 4). Once these issues have been 
positively excluded, and gastrointestinal disorders may be reasonably suspected, a diagnostic 
workup should be started (Figure 4). The clinical background should help in the diagnostic 
strategy, particularly when refractory iron-deficient anemia is concurrently present (219): this 
kind of anemia is, in fact, often associated to H. Pylori infection (220), celiac disease (221), 
and atrophic gastritis, prior to pernicious anemia (219). These latter are frequently associated 
with autoimmune hypothyroidism in the type III polyglandular autoimmune syndrome (98, 
138, 222, 223) even in young patients (223, 224). A previous or active H. pylori infection 
must be screened as a first line as it is the most prevalent disorder (102). Either 14C-Urea 
breath test or fecal H.pylori antigen detection and the measurement of antibodies against H. 
Pylori should be performed (102). If positive, following the appropriate treatment, the 
involvement of gastric mucosa should be investigated by endoscopy with multiple biopsies 
(225). Once the H. Pylori infection has been excluded, other possibilities should be 
investigated by measuring the anti-parietal cell antibodies (APCAb) and fasting gastrinemia 
(226). High serum gastrin levels and the presence of APCAb support the suspicion of an 
autoimmune gastric atrophy (227) and again performing endoscopy with multiple biopsies of 
gastric body and antrum is strongly suggested (94). In the presence of iron deficient anemia 
and/or abdominal bloating and pain and/or chronic diarrhea, celiac disease deserves attention 
(136). The assessment of anti transglutaminase antibodies (tTgAb) and total serum IgA levels 
may help to diagnose celiac disease (136) but, once again, only endoscopy may confirm or 
exclude the presence of this disease (228). If the suspicion concerns other intestinal disorders, 
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the diagnostic workup should include some breath tests (lactose, glucose, lactulose) able to 
detect lactose intolerance (229), bacterial overgrowth (230) and/or altered transit time in the 
gut (230), respectively.  These breath test  have been considered reliable, useful and safe tools 
in diagnose carbohydrate maldigestion, being also the least invasive tools to diagnose SIBO 
(231). Finally, the stool examination should be kept in mind when parasitism is suspected 
(e.g. Giardia lamblia) (164). Many of the described gastrointestinal disorders may occur in a 
hidden or even occult way (Figure 2). In this case, the diagnostic workup should be driven by 
the prevalence of each diseases, taking into account patient’s and his/her familial medical 
history. A successful diagnostic workup may uncover the vast majority of gastrointestinal 
cause of poor response to thyroxine treatment, but would also be useful to diagnose and treat 
these silent, but not harmless, gastrointestinal disorders. In this view, malabsorption of T4 
may represent a tool to diagnose occult gastrointestinal diseases.  
ALTERNATIVE Pharmacologic Perspectives    
While the tablet formulation of thyroxine remains the gold standard in the treatment of 
hypothyroidism, hormone paraphernalia evolved. The “difficult patient” as described by 
Laura Ward (218) is probably more than an exception in the treatment of hypothyroidism. 
The most recent advance concerning thyroxine treatment stems from the growing attention to 
alternative oral formulations: the liquid preparation and the softgel capsule. The soft gel 
capsule contains, in an outer gelatine shell, T4 dissolved in glycerine (23). This structure 
warrants a rapid dissolution in the acid gastric environment (232). The liquid formulation is 
composed of T4, glycerine and ethanol and its most important feature is that it does not 
require a gastric dissolution (16). A 2-way crossover, bioequivalence study in 84 healthy 
subjects has been carried out to compare T4 tablets, soft gel capsules and oral solution (21). 
Mean pharmacokinetic parameters were not statistically different between these formulations; 
however, a faster absorption of thyroxine solution was observed probably because of the lack 
of the dissolution phase (21). It is beyond the scope of the present review to analyze in detail 
the advantages and disadvantages of alternative preparations of thyroxine, which were, 
however, recently reviewed elsewhere (233). Here we analyzed the studies concerning the 
possible use of these alternative preparations in patients with gastrointestinal disorders. In a 
prospective study in 31 patients with gastric-related T4 malabsorption, stably treated with 
tablet thyroxine preparation and switched to softgel T4, the effective dose of this latter 
preparation was significantly reduced in about 2/3 of patients (234). More recently, very 
preliminary data suggested that the switch from tablet to softgel T4 preparation at unchanged 
dose improved TSH even in patients taking pill 30’ before the breakfast (235). Furthermore, 
softgel T4 preparation helps to overcome the problem of coffee PPI interference on tablet T4 
treatment (236, 237).  
The obvious and most important advantage of the liquid T4 solution is the possibility of 
administration in pediatric age (238-240) or in patients who are not able to swallow tablets or 
capsules (233, 241). In hypothyroid newborns and infants the daily thyroxine dosage is 
calculated according to age and T4 tablets are usually crashed and given with liquids (239, 
240). In these little patients, liquid thyroxine formulation is easily managed and administered 
and may is also better absorbed than the tablet formulation (240). The European Society for 
Paediatric Endocrinology (ESPE) guidelines acknowledged this alternative treatment in 
pediatric age (242). In adult hypothyroid patients, some studies analyzed whether the 
restraints of tablet thyroxine treatment may be overcome by the use of this preparation: i.e., 
whether the foods may interfere with liquid thyroxine absorption as they do with tablet 
formulation (243, 244). A double blind, randomized, placebo-controlled, crossover trial 
suggested that a liquid T4 formulation could be ingested directly at breakfast, potentially 
improving therapeutic compliance (244) by reducing one of the major issues in the treatment 
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with tablet T4: the negative impact of breakfast on the treatment efficacy (31, 36, 37, 40, 244, 
245). Liquid thyroxine preparation was tested even in patients with gastrointestinal 
malabsorption.  In fact, in a prospective observational study, the liquid preparation has been 
proven to overcome T4 malabsorption induced by the increased gastric pH due to PPI 
treatment (246) and by lactose intolerance (247). Similarly, in a case series, it has been shown 
that oral liquid formulation might bypass the pH alteration due to atrophic gastritis in patients 
who were still hypothyroid when treated with tablet thyroxine (248). As previously discussed 
above, drug malabsorption is a potential concern after bariatric surgery. In a recent study, 
hypothyroid patients, well replaced with thyroxine tablets before surgery (13 RYGB; 4 
biliary pancreatic diversions (BPD), showed an increased TSH 3 to 8 months after surgery 
(181); the switch to liquid T4, at the same dose, significantly improved TSH values also in 
patients with BPD, confirming previous studies in patients submitted to RYGB (180). 
Despite some encouraging results in patients with gastrointestinal malabsorption the 
overall analysis of these studies revealed some limitations: the entire field deserves further 
systematic studies before drawing definite conclusions (249). 
Concluding Remarks  
Gastrointestinal malabsorption of oral thyroxine is more frequent than previously reputed and 
may account for a significant fraction of refractory hypothyroidism. On this ground, an 
accurate individualization of hormonal treatment helps in the detection of gastrointestinal T4 
malabsorption. Although the site of thyroxine absorption is the small intestine, gastric pH 
emerges as a major prerequisite for the efficacy of tablet thyroxine treatment. An increased 
need for thyroxine should induce endocrinologist to start a diagnostic workup, based on the 
clinical features and on the prevalence of gastrointestinal disorders.  
Despite the growing number of studies, some questions are far from being clarified. The 
pathophysiologic mechanisms of thyroxine absorption at the intestinal level are not yet 
completely defined as shown in the real life by a number of patients in whom the cause of an 
increased need for T4 remain obscure. In particular, the intestinal transport pathways, the 
actual contribution of the enterohepatic recycling and the role of microbiota composition in 
the absorption of thyroxine in humans are issues for future studies. 
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Figure 1. Different ionization status of the three ionizable moieties of the thyroxine molecule 
at different medium pH. pKa1: ionization constant of the carboxyl group. pKa2: ionization 
constant of the phenolic group. pKa3: ionization constant of the amino group  
Figure 2. Main pathologic and post-surgical conditions leading to thyroxine malabsorption. 
Arrows indicate the progressively lower frequency of these disorders. Diseases have been 
subdivided based on the primitive site involved (stomach and intestine).  
Figure 3. Nutrients, foods and drugs interfering with thyroxine absorption. In the yellow 
circle: gastric level as the prevalent site of interference. In the red circle: intestinal level as 
the prevalent site of interference. In the orange overlapping part: interference exerted at both 
gastric and intestinal levels. 
Figue 4. Diagnostic work up for the main pathologic gastrointestinal causes of thyroxine 
malabsorption based on the clinical ground and/or the prevalence of each disorder in the 
general population. Grey boxes: issues that must be excluded before starting diagnostic work 
up. Orange boxes: diagnosed disease. Green boxes: diagnostic method. 
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Table 1. Excipients in T4 tablet formulations. 
 Tablet, brand Tablet, generic 
 1 2 3 4 5 6 7 8 9 10 11 
Cellulose √ √  √ √  √   √  
Talc  √    √ √     
Povidone    √  √      
Colloidals silicone 
dioxide 
 √        √  
Starch  √ √   √ √ √ √ √ √ 
Acacia      √  √    
Gelatin   √         
Mg stearate ± stearic 
acid 
√ √ √ √ √ √ √ √ √ √ √ 
Na croscarmellose √  √  √       
Na citrate       √ √    
Na carboxymethylamide       √     
Ca phosphate    √   √     
Ca sulphate     √       
Bicarbonate     √       
Lactose √  √   √  √ √  √ 
Dyes (color additives) √    √ √      
TABLET, BRAND- 1= Bagothyrox (Quimica Montpelier); 2= Eltroxin (GlaxoSmithKline); 3= Euthyrox 
(Merck); 4= Levothroid (Forest/Sanofi Aventis); 5= Levoxyl (Jones/King Pharmaceuticals); 6= Synthroid 
(Abbott); 7= Tirosint (IBSA Farmaceutici Italia srl);  
TABLET, GENERIC- 8= (Mercury); 9= (Almus); 10= (Sandoz); 11= (Actavis) 
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pKa2
CATION
ZWITTERION ANION
DIANION
ACIDIC ALKALINE
ENVIRONMENTAL pH VALUES
2.04 6.71 8.85
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GASTROINTESTINAL MALABSORPTION 
OF THYROXINE: DISEASES AND 
DISORDERS
LACTOSE  MALDIGESTION
CELIAC DISEASE
SMALL INTESTINE 
BACTERIAL OVERGROWTH
PARASITIC DISEASES
HELICOBACTER PYLORI 
INFECTION
GASTRIC ATROPHY
MOTILITY IMPAIRMENTS
FREQUENTLY OCCULT
LIVER CIRRHOSIS
RYGB GASTRIC
BANDING
SLEEVE 
GASTRECTOMY
SHORT BOWEL
SYNDROME
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PANGASTRITIS
CLINICALLY EVIDENT
PANCREATIC STEATORRHEA
BILIOPANCREATIC
DIVERSION
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CARBONATE
ALUMINUM 
HYDROXIDE
SUCRALFATE
MILK
PAPAYA
CALCIUM 
CITRATE
CALCIUM 
ACETATE
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SULFATE
BILE ACID 
SEQUESTRANTS
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SOY
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TKI
Β-BLOCKERS
GRAPEFRUIT JUICE
CIPROFLOXACINE
TRICYCLIC 
ANTIDEPRESSANTS
GASTRIC INTESTINAL
NUTRIENTS, FOODS AND DRUGS: 
PREVAILING SITE OF INTERFERENCE WITH THYROXINE 
ABSORPTION
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SUSPECT GASTROINTESTINAL 
MALABSORPTION OF THYROXINE
Urea Breath Test/ fecal antigen 
and  serum HP Ab
Gastrinemia 
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Lactose Breath Test
tTGAb /total IgA
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GASTRODUODENALENDOSCOPY WITH 
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Glucose Breath test
Lactulose Breath test
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H. Pylori infection
eradication
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Lactose Maldigestion
Lactose-free diet
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Antibiotic 
treatment
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Gluten-free diet Follow upSpecific treatment
Pseudomalabsorption 
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